Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Deutsche Grundstücksauktionen sees Q4 sales, earnings rising year on year on improved market conditions

Deutsche Grundstücksauktionen sees Q4 sales, earnings rising year on year on improved market conditions

ReutersReuters2026/09/14 10:19
  • Deutsche Grundstücksauktionen sees a chance to lift revenue and earnings in Q4 versus the prior year on improved market conditions.
  • Q3 auctions and brokerage sales totaled EUR 22.7 million across 289 properties, marking the highest quarterly turnover since Q4 2022.
  • Object turnover rose 10.5% year on year in Q3, despite continued buyer caution for some larger assets.
  • Net income from premiums and commissions was about EUR 1.98 million in Q3, broadly in line with EUR 2.04 million a year earlier.
  • First nine months of 2025 sales reached about EUR 60.2 million across 919 properties, up 6.25% year on year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Deutsche Grundstücksauktionen AG published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage